Subscribe To
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Roche enters into a definitive agreement to acquire telavant including rights to novel tl1a directed antibody (rvt-3101) for the treatment of inflammatory bowel disease from roivant
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the trea...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 23, 2023, 5:00 am
Roche splashes us$7.1 billion on new irritable bowel drug
Roche has agreed to pay US$7.1 billion for an early-stage inflammatory bowel disease treatment develop...
October 23, 2023, 4:44 am
Indivior to pay $385 mln to end suboxone monopoly lawsuits
Drugmaker Indivior said on Monday it will pay $385 million to settle a lawsuit brought by direct purchasers on claims it illegally suppressed generic ...
October 23, 2023, 2:36 am
Roche buys telavant holdings for $7.1 billion
Roche on Monday said it will buy Telavant, a developer of a new treatment for inflamatory bowel disease...
October 23, 2023, 1:37 am
Toyota lobbies india to cut hybrid-car taxes as much as 21% - letter
Japan's Toyota Motor is lobbying the Indian government to cut taxes on hybrid vehicles by as much as one-fifth, arguing they are far less polluting th...
October 22, 2023, 9:37 pm
Mallinckrodt to present data on terlivaz® (terlipressin) for injection in adult patients with hepatorenal syndrome (hrs) at the american college of gastroenterology (acg) annual scientific meeting
– Findings from two clinical studies and one health economic database analysis provide insight into HRS trea...
October 22, 2023, 3:05 pm
Scammers exploit bitcoin atms. will new california laws help crack down on fraud?
California is capping crypto atm transactions and fees along with creating new licensing requirements f...
October 22, 2023, 10:29 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
